Viatris Inc Ord Shs Stock Price, News & Analysis

Viatris (Nasdaq: VTRS) has announced its participation in two major healthcare conferences in November 2024. The company will attend the UBS Global Healthcare Conference on November 12 at the Terranea Resort in California, with a fireside chat scheduled for 8:45 a.m. PT. Additionally, Viatris will participate in the Jefferies London Healthcare Conference on November 21 at the Waldorf Hilton Hotel in London, with a session at 10:30 a.m. GMT.

Both events will feature fireside chats with Viatris executives and will be accessible via live webcasts at investor.viatris.com, with archived versions available for time after the events.

Viatris Inc. (Nasdaq: VTRS) has entered an exclusive licensing agreement with Lexicon Pharmaceuticals for sotagliflozin in all markets outside the U.S. and Europe. Sotagliflozin, approved by the FDA in May 2023, reduces cardiovascular risks in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.

This agreement leverages Viatris' expertise in cardiovascular diseases and its Global Healthcare Gateway®. Viatris will pay Lexicon an upfront payment of $25 million, with additional potential contingent payments including regulatory milestones, sales milestones, and tiered royalties ranging from low-double-digit to upper-teens on annual net sales. Viatris will handle regulatory and commercialization activities in licensed territories, while Lexicon will provide clinical and commercial supply of sotagliflozin.

Viatris has released its 2023 Sustainability Report, highlighting extensive efforts in India to address critical health and social needs. Key initiatives include:

• Supporting Akshaya Vidya, a supplementary education program for underprivileged children.
• Developing a watershed in Ranga Reddy District to boost groundwater and agricultural productivity.
• Partnering with Sportz Village Foundation to promote fitness among children in Hyderabad.

In cancer care, Viatris, in collaboration with Tata Memorial Center, has screened over 8 million people for oral cancer, expanding from six districts to all 34 in Maharashtra and to six other states. The Healthy Liver Healthy Delhi program has provided over 30,000 liver health screenings since 2017. Viatris also supports sustainable farming practices and is working to address tuberculosis (TB) through multiple community programs, benefiting over 80,000 people in 2023.

Viatris, a global healthcare company, has released its 2023 Sustainability Report highlighting efforts to reduce packaging materials. Key initiatives include:

• Reducing paper use by 90 metric tons at oral-solid dose manufacturing sites
• Cutting 2 metric tons of plastic and 5 metric tons of wood through bulk packaging optimization
• Replacing 88 metric tons of plastic with polythene bags
• Reducing plastic use by 18 metric tons through shrink bundle film optimization

The company is also exploring e-labeling, implementing PCTFE mitigation in blister packaging, and pursuing carton-less initiatives. Viatris is working on harmonizing packaging across markets, including the use of quadrilingual packs to reduce the need for individual language-specific bottles. In Cairo, Egypt, the facility has started reusing empty supply carton boxes, saving four tons annually.

Viatris Inc. (NASDAQ: VTRS) announced positive top-line results from its Phase 3 study of EFFEXOR® (venlafaxine) in Japanese adults with Generalized Anxiety Disorder (GAD). The study met its primary objective, demonstrating superiority of EFFEXOR® over placebo in anxiolytic effects at 8 weeks. All seven secondary efficacy endpoints were also met.

EFFEXOR® was generally well tolerated, with low discontinuation rates due to adverse events and no serious adverse events observed. The company plans to submit to the Pharmaceuticals and Medical Devices Agency (PMDA) in 2025. This study is significant as there are currently no approved treatments for GAD in Japan.

Viatris Inc. (NASDAQ:VTRS), a global healthcare company, has been named to Forbes' list of World's Best Employers 2024 for the fourth consecutive year. This recognition, presented by Forbes and Statista, is based on an independent survey of over 300,000 participants across 50 countries.

Andrew Enrietti, Chief People Officer at Viatris, attributed this achievement to the company's strong culture that prioritizes employee well-being, inclusivity, diversity, growth opportunities, and work-life balance. The selection process involved participants rating their willingness to recommend their employer and reviewing various aspects of employment.

This recognition follows Viatris' inclusion in other prestigious lists such as TIME's World's Most Sustainable Companies 2024, USA Today's America's Climate Leaders 2024, and 3BL's 100 Best Corporate Citizens of 2023. The company has also received Great Place to Work® certifications and Top Employers certifications in multiple countries.

Viatris Inc. (NASDAQ: VTRS), a global healthcare company, has been named to Forbes' list of World's Best Employers 2024 for the fourth consecutive year. This recognition, presented by Forbes and Statista, is based on an independent survey of over 300,000 participants across 50 countries.

Andrew Enrietti, Chief People Officer at Viatris, attributed this achievement to the company's focus on its people and strong culture, which prioritizes well-being, inclusivity, diversity, growth opportunities, and work-life balance. The survey assessed employees' willingness to recommend their employer and their reviews of various employment aspects.

This accolade follows Viatris' inclusion in other prestigious lists such as TIME's World's Most Sustainable Companies 2024, USA Today's America's Climate Leaders 2024, and 3BL's 100 Best Corporate Citizens of 2023. The company has also received Great Place to Work® and Top Employers certifications in multiple countries.

Viatris has released its 2023 Sustainability Report, highlighting expanded contractor training initiatives. The company is constructing a new injectable manufacturing facility in Krishnagiri, India, emphasizing safety as a top priority. The project has achieved 2.3 million incident-free man hours and is expected to be completed by early 2025.

Key safety initiatives implemented at the 69,000 square meter site include:

• Establishing a Safety Park for equipment overview
• Providing nearly 8,000 manhours of EHS trainings
• Deploying a "Permit to Work" program with approximately 23,000 permits issued
• Implementing a reward program for exemplary safety performance

Jayesh Thakor, Senior Director - EHS Injectable India at Viatris, expressed pride in the project's safety record and thanked the EHS team, contractors, and project team for their support in achieving safety goals.

Viatris' facility in Komárom, Hungary, has joined the Bird-Friendly Workplace Program in partnership with the Hungarian Ornithological Society. The site, located near the Danube River, encompasses about 4 hectares of diverse habitat for birds and insects. In February 2024, the team installed 50 bird houses and established a breeding wall, expecting to attract about 40 different bird species.

The initiative was proposed by Róbert Klinga, a Quality Control Support Manager and bird enthusiast. The project aims to enhance biodiversity and raise awareness about environmental conservation. As part of the program, Viatris organized a Bird-Friendly Family Day for employees, featuring activities like bird ringing and burrow checks. This effort aligns with Viatris' commitment to sustainability and reducing environmental impact in its operations.